What Is Drug Antibody Ratio (DAR) And How It Relates To Biotherapeutics?

This content is brought to you by Phenomenex, a Danaher Operating Company.

Drug-to-antibody ratio (DAR) plays a central role in how antibody-drug conjugates perform, shaping everything from potency and tolerability to stability, pharmacokinetics, and manufacturability. While many approved ADCs fall within a DAR range of roughly 2–8, there is no universal “ideal” number. The optimal DAR depends on the payload, linker design, target biology, and conjugation strategy, making precise control and reliable measurement essential at every stage of development. As ADC pipelines grow and regulatory expectations become more rigorous, DAR analysis has become a foundational requirement for demonstrating product quality and consistency.

Explore why DAR matters, how it influences ADC behavior, and why robust analytical approaches are critical for development, manufacturing, and quality control.